Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).Xīn Gào, Daniel P. Petrylak, Arash Rezazadeh Kalebasty et al.|Journal of Clinical Oncology|2022Cited by 192
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trialDaniel P. Petrylak, Cristiano Ferrario, Ronald de Wit et al.|The Lancet|2017Cited by 177
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trialDaniel P. Petrylak, Siobhan Ng, Ronald de Wit et al.|The Lancet Oncology|2019Cited by 87
1803P Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with AR ligand-binding domain (LBD) mutationsDaniel P. Petrylak, Xīn Gào, Benjamin Garmezy et al.|Annals of Oncology|2023Cited by 10